Stock Taper 
Corvus Pharmaceuticals, a clinical-stage biopharma in Burlingame, develops immuno-oncology therapies like Mupadolimab, CPI-818, and Ciforadenant, with ongoing trials targeting cancers and collaborations to advance its pipeline.
Soquelitinib is an investigational oral drug by Corvus Pharmaceuticals targeting ITK, in clinical trials for immune diseases and cancers, including Phase 3 for T-cell lymphomas and Phase 2 for atopic dermatitis.
In December 2025, Corvus Pharmaceuticals' stock experienced a significant pre-market drop of 5.36% following a regulatory filing that suggested potential delays in the FDA's review of Phase III trial data for its key oncology drug, soquelitinib. This news raised concerns among investors regarding the company's clinical and regulatory timelines, leading to increased market sensitivity and a notable negative impact on the stock price.
In 2025, Corvus Pharmaceuticals made a significant strategic shift by prioritizing the development of its lead drug candidate, soquelitinib, for the treatment of moderate to severe atopic dermatitis. This move represents a major expansion from its initial focus on oncology into the large and competitive immunology market, driven by promising Phase 1 clinical trial data.
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS - Get Free Report)'s stock price gapped up before the market opened on Tuesday. The stock had previously closed at $11.87, but opened at $12.37. Corvus Pharmaceuticals shares last traded at $11.8020, with a volume of 159,690 shares changing hands. Wall Street Analysts Forecast Growth A number of brokerages have recently
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that enrollment has begun in its Phase 1b clinical trial of soquelitinib for the treatment of patients with hidradenitis suppurativa.
Overall rating: C-
| PEER | PRICE | |
|---|---|---|
 RCUS | $24.52 | COMPARE |
 ABSI | $10.50 | COMPARE |
 NKTR | $38.98 | COMPARE |
 OLMA | $7.99 | COMPARE |
 VSTM | $7.74 | COMPARE |
 CTMX | $2.54 | COMPARE |
 PRTA | $8.04 | COMPARE |
 RGNX | $7.54 | COMPARE |
